DALLAS, July 26, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC:RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that it has filed it’s S1 and has completed mid-year strategy review in conjunction with the filing.
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here